There are currently 1184 clinical trials in Pittsburgh, Pennsylvania looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Pittsburgh, University of Pittsburgh Medical Center, Alleghany General Hospital and Children's Hospital of Pittsburgh UPMC. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Machine-Learning Prediction and Reducing Overdoses with EHR Nudges
NCT06806163
Recruiting
The goal of this cluster randomized clinical trial is to test a clinician-targeted behavioral nudge intervention in the Electronic Health Record (EHR) for patients who are identified by a machine-learning based risk prediction model as having an elevated risk for an opioid overdose. The clinical trial will evaluate the effectiveness of providing a flag in the EHR to identify individuals at elevated risk with and without behavioral nudges/best practice alerts (BPAs) as compared to usual care by... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/13/2025
Locations: University of Pittsburgh, Pittsburgh, Pennsylvania
Conditions: Opioid Overdose, Opioid Use, Opioid Use Disorder, Opioids
Register for Updates
Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer
NCT03851445
Recruiting
This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid Master Protocol (Lung-MAP). The type of cancer trait (biomarker) will determine to which sub-study, within this protocol, a participant will be assigned to compare new targeted cancer therapy, designed to block the growth and spread of cancer, or combinations to standard of... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/12/2025
Locations: UPMC-Saint Margaret, Pittsburgh, Pennsylvania +4 locations
Conditions: Previously Treated Non-Small Cell Lung Cancer
Register for Updates
ETHAN - ET for Male BC
NCT05501704
Recruiting
This research study is looking to see how well male breast cancer responds to preoperative treatment with endocrine therapy and which endocrine therapy regimen is the most effective treatment for male breast cancer. The drugs used in this study are: * Tamoxifen * Anastrozole * Degarelix * Abemaciclib
Gender:
MALE
Ages:
18 years and above
Trial Updated:
03/12/2025
Locations: University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania
Conditions: Male Breast Cancer, Hormone Receptor-positive Breast Cancer, Hormone Receptor Negative Breast Carcinoma
Register for Updates
Pembrolizumab/Lenvatinib With and Without Healthy Donor FMT (hdFMT) in Relapsed/ Refractory (R/R) Melanoma
NCT06030037
Recruiting
In this is a randomized phase II study the addition of hd-FMT (healthy donor fecal-microbiota transplant) to pembrolizumab /lenvatinib in PD-1 R/R melanoma will be evaluated over a 104-week period in patients with anti-PD-1 R/R disease. Patients with PD-1 refractory advanced melanoma are eligible to enroll, excluding patients with prior lenvatinib (or other TKI) exposure. Intestinal microbiome composition mediates response to anti-PD-1 by affecting systemic inflammatory tone.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/12/2025
Locations: UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania
Conditions: PD-1 Refractory Advanced Melanoma
Register for Updates
Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma
NCT06070012
Recruiting
This is a phase II open-label, single-arm, multi-center study of tebentafusp in HLA- A\*0201 positive previously untreated (1L) untreated metastatic uveal melanoma (mUM) with an integrated circulating tumor DNA (ctDNA) biomarker.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/12/2025
Locations: UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania
Conditions: Uveal Melanoma
Register for Updates
BioButton Among Nursing Home Residents
NCT06665685
Recruiting
This pilot study will explore the use of the BioIntellisense BioButton, a remote wearable multi-parameter monitor, to identify gait disturbances that occur as a side effect of polypharmacy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/12/2025
Locations: UPMC Canterbury Place, Pittsburgh, Pennsylvania
Conditions: Gait, Medication Induced Gait Disturbances
Register for Updates
Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy
NCT02945579
Recruiting
This clinical trial studies eliminating surgery and how well radiation therapy after systemic therapy works in treating patients with HER2 positive or triple negative breast cancer when image-guided biopsy shows no residual cancer. Patients then receive standard breast radiotherapy.
Gender:
FEMALE
Ages:
30 years and above
Trial Updated:
03/11/2025
Locations: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
Conditions: Estrogen Receptor Negative, HER2 Positive Breast Carcinoma, HER2/Neu Negative, Invasive Breast Carcinoma, Progesterone Receptor Negative, Stage I Breast Cancer AJCC v7, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7, Stage II Breast Cancer AJCC v6 and v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Triple-Negative Breast Carcinoma
Register for Updates
MCNAIR Study: coMparative effeCtiveness of iN-person and teleheAlth cardIac Rehabilitation
NCT05933083
Recruiting
Cardiac rehabilitation is a medically recommended program for patients with certain heart conditions. It includes exercise training, health education, and counseling. Unfortunately, many patients do not participate in cardiac rehabilitation. Some find it challenging to attend the in-person sessions. This study aims to compare two methods of delivering cardiac rehabilitation: in-person and through telehealth. The investigators want to know if the effects of these two programs are alike and if cer... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/11/2025
Locations: University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania
Conditions: Myocardial Infarction, Heart Failure, Systolic, Heart Valve Diseases, Angina, Stable, Coronary Artery Disease, Heart Transplant
Register for Updates
A Study of CBX 12 in Subjects With Platinum Resistant or Refractory Ovarian Cancer
NCT06315491
Recruiting
The purpose of this study is to assess the safety, tolerability, and efficacy of CBX-12 in female subjects with platinum resistant or refractory ovarian cancer at 2 doses; 125 mg/m2 every 21 days or 100 mg/m2 every 21 days.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
03/11/2025
Locations: Allegheny Singer Research Institute D/B/A Ahn Research Institution, Pittsburgh, Pennsylvania
Conditions: Platinum-resistant Ovarian Cancer, Refractory Ovarian Carcinoma
Register for Updates
The Impact of Standardized Tobacco Product Packaging on Young Adults in the Retail Environment
NCT05973981
Recruiting
The overall aim of this research is to experimentally evaluate the extent to which partially standardizing the color of tobacco packaging influences tobacco use intentions among young adults who have varying levels of tobacco use experience.
Gender:
ALL
Ages:
Between 21 years and 29 years
Trial Updated:
03/10/2025
Locations: RAND Corporation, Pittsburgh, Pennsylvania
Conditions: Smoking, Cigarette
Register for Updates
Metformin for Pulmonary Hypertension HFpEF
NCT03629340
Recruiting
The main objective of this study is to determine the clinical efficacy of metformin versus placebo and the therapeutic response with regards to functional capacity and hemodynamics in PH-HFpEF.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/07/2025
Locations: University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania
Conditions: Pulmonary Hypertension, Heart Failure
Register for Updates
A Study of DR-01 in Subjects With Alopecia Areata and Vitiligo
NCT06602232
Recruiting
This is a multi-center, parallel-group, open-label, randomized, Phase 1b study to explore the safety, clinical activity, pharmacokinetics and pharmacodynamics of DR-01 in adults with Alopecia Areata or Vitiligo.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/05/2025
Locations: Dren Investigational Site, Pittsburgh, Pennsylvania
Conditions: Alopecia Areata, Vitiligo
Register for Updates